AMENDMENTS TO THE CLAIMS

Docket No.: 20241/0203481-US0

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound represented by formula (1):

(wherein,

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

$$(R2)$$
 n $(R3)$ p $(R3)$ p $(R4)$

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more),

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more), and

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a thiochroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom,

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent), or a pharmaceutically acceptable salt thereof.

Claim 2 (original): A compound or pharmaceutically acceptable salt according to claim 1, wherein z is a group represented by the following formula (A), (B) or (C):

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent)).

and the Handle and according to

Docket No.: 20241/0203481-US0

Claim 3 (currently amended): A compound or pharmaceutically acceptable salt according to claim 1-or-2, wherein A is 1-imidazolyl or 1-H-pyrazole-5-yl which is substituted at the fourth position on the benzene ring.

Claim 4 (original): A production process of a compound represented by formula (1): (wherein,

$$\begin{array}{c}
A \\
N - CO - B - Z
\end{array} (1)$$

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

$$N \stackrel{(R2) n}{=} N \stackrel{(R3) p}{=} R4$$

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1, R4 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1, a C₁₋₆ alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

Application No. Not Yet Assigned Amendment dated October 12, 2005 First Preliminary Amendment

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more),

7

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more),

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a thiochroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom, and

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent), comprising:

a step 1 in which a compound represented by the following formula (1')

$$\stackrel{A}{\swarrow} \stackrel{N-C0-B-Z'}{\stackrel{\cdot}{R}_1} (1')$$

(wherein

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

$$(R2)$$
 n $(R3)$ p

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more)),

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more), and

Z' is represented by the following formula (A)', (B)', or (C)':

 ${W:\20241\0203481us0\00548791.DOC \cite{Model Model Model Model Model}}$

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent))

is produced by reacting an amine compound represented by formula (2):

$$\begin{array}{c}
A \\
N \\
R1
\end{array}$$
(2)

(wherein

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

$$N = N$$
 (R2) n

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1, R4 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1, a C₁₋₆ alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more))

with a compound represented by the following formula (3):

$$YOC-B-Z'$$
 (3)

(wherein

Y represents a hydroxyl group or a halogen atom,

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkenyloxy group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more) and

Z' is represented by the following formula (A)', (B)', or (C)':

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C₁₋₆ alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C₁₋₆ alkylcarbonyl group, or a benzoyl group which may have a substituent)); and

a step 2 in which the nitro compound produced in the step 1 is converted to an amino group using a reducing agent.

Claim 5 (original): An antioxidant comprising as its active ingredient at least one compound represented by formula (1):

$$\begin{array}{c}
A \\
\hline
N - CO - B - Z
\end{array} \tag{1}$$

(wherein

R1 represents a hydrogen atom or a C₁₋₆ alkyl group which may be substituted,

A represents an imidazolyl group or a pyrazolyl group represented by the following formulae:

Application No. Not Yet Assigned Amendment dated October 12, 2005 First Preliminary Amendment

$$(R2)$$
 n $(R3)$ p $(R3)$ p $(R4)$

(wherein

R2 and R3 represent a hydrogen atom or a C₁₋₆ alkyl group which may be substituted by G1,

R4 represents a hydrogen atom or a C_{1-6} alkyl group which may be substituted by G1, a C_{1-6} alkylcarbonyl group which may be substituted by G1, or a benzoyl group which may be substituted by G1,

n represents 0 or an integer of 1 to 3,

p represents 0 or an integer of 1 or 2, and

R2 and R3 may be identical to each other, or different from each other, when n and p are 2 or more)),

B represents a group represented by the following formula:

(wherein

R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl

group, a C_{2-6} alkenyloxy group, a C_{2-6} alkynloxy group, a C_{1-6} acyloxy group, or a C_{3-6} cycloalkyl group, or a phenyl group which may have a substituent,

k represents 0 or an integer of 1 to 15, and

R5 and R6 may be identical to each other, or different from each other, when k is 2 or more),

Z represents a chroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzofuran-2-yl group which is substituted by G2, a thiochroman-2-yl group which is substituted by G2, a 2,3-dihydrobenzothiophene-2-yl group which is substituted by G2, or a 1,3-benzoxathiol-2-yl group which is substituted by G2,

G1 represents a cyano group, a formyl group, a hydroxyl group, an amino group, a dimethylamino group, or a halogen atom, and

G2 is represented by the following formula: NHR (wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent) or a pharmaceutically acceptable salt thereof.

Claim 6 (original): An antioxidant according to claim 5, wherein in formula (1) z is represented by the following formula (A), (B), or (C):

Application No. Not Yet Assigned Amendment dated October 12, 2005 First Preliminary Amendment

(wherein

* represents an asymmetric carbon atom,

X1 represents an oxygen atom or a sulfur atom,

R7 to R17 each independently represents a hydrogen atom or a C_{1-6} alkyl group, and

G2 is represented by the following formula: NHR

(wherein R represents a hydrogen atom, a C_{1-6} alkylcarbonyl group, or a benzoyl group which may have a substituent)).

Claim 7 (original): A kidney disease, cerebrovascular or cardiovascular disease treatment agent characterized by comprising the antioxidant according to claim 6.

Claim 8 (original): A cerebral infarction treatment agent characterized by comprising the antioxidant according to claim 6.

Claim 9 (original): A retinal oxidation disorder inhibitor characterized by comprising the antioxidant according to claim 6.

17

Docket No.: 20241/0203481-US0

Claim 10 (original): A retinal oxidation disorder inhibitor according to claim 9 for agerelated macular degeneration or diabetic retinopathy.

Claim 11 (original): A lipoxygenase inhibitor characterized by comprising the antioxidant according to claim 6.

Claim 12 (original): A 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor characterized by comprising the antioxidant according to claim 6.

Claim 13 (new): A compound or pharmaceutically acceptable salt according to claim 2, wherein A is 1-imidazolyl or 1-H-pyrazole-5-yl which is substituted at the fourth position on the benzene ring.